Glucose is used as an energy source in most organisms, from bacteria to humans. The facilitative glucose transport systems are ubiquitous in living cells and are responsible for the movement of glucose across the cell membrane. Since transport of glucose is essential for life and is carefully regulated, glucose uptake assays are performed in a vast number of biological studies. Previously, the method of choice employed radio-labeled hexose derivatives, but now researchers can select several non-radioisotopic methods to evaluate glucose uptake. In the present review, we introduce the various methodologies used to conduct glucose uptake assays and evaluate their application.
Introduction
Facilitative glucose transport systems are ubiquitous and are responsible for the movement of glucose across the cell membrane. In higher organisms, the preservation of energetic integrity requires adaptation to external resources and extensive inter-organ communication. In this context, glucose has acquired a role as a signaling molecule to control glucose and energy homeostasis. Glucose can regulate gene transcription, enzyme activity, hormone secretion, and the activity of glucoregulatory neurons. A number of diseases are associated with glucose transport and metabolic disorders, including myocardial ischemia (Schelbert and Buxton, 1988) , Type 2 diabetes (T2DM) (DeFronzo et al., 1985) , and cancer (Rigo et al., 1996) .
In general, glucose is transported across membranes by two different mechanisms: an Na + -coupled active carrier system (SGLT), and a family of structurally related Na +independent glucose transporter glycoproteins. These latter, which are known as the glucose transporter (GLUT) or SLC2A family, facilitate the movement of glucose across the plasma membrane down its chemical gradient either into or out of cells. GLUTs are specific for d-glucose and/or related hexoses and are not coupled to any energy-requiring components, such as ATP hydrolysis or an H + gradient. In an attempt to explain the isomeric specificity and saturability of glucose uptake into human red blood cells, LeFevre postulated that a specific component within the cellular plasma membrane was required for the transfer of glucose across the lipid bilayer (LeFevre, 1948) . In the 1970s, glucose transport was demonstrated to be mediated by a protein embedded in the erythrocyte plasma membrane that could be partially purified and functionally reconstituted into proteoliposomes (Baldwin et al., 1981; Kasahara and Hinkle, 1977) . Then, in 1985, the first transporter, GLUT1, was cloned (Mueckler et al., 1985) ; to date, 14 isoforms of the GLUT family have been identified. GLUTs are proteins composed of ~ 500 amino acids and are predicted to possess 12 transmembranespanning alpha helices and a single N-linked oligosaccharide. The GLUT family members can be grouped into three different classes based on their sequence similarities (Thorens and Mueckler, 2010) . These hexose transporters are distinct from the Na + -dependent co-transporters which actively accumulate glucose. They catalyze the facilitative (energy-independent) face. The physiological roles of GLUTs are related to their kinetic and substrate specificities, with numerous studies aimed at defining these properties of GLUT isoforms. However, because glucose is rapidly metabolized and its transport is not always rate-limiting, nonmetabolizable analogs, such as 2-deoxy-d-glucose (2DG) and 3-O-methylglucose (3MG), are generally used as glucose tracers for studying glucose transport ( Figure 3 ). Nowadays, researchers can select several non-radioisotopic methods in order to evaluate glucose uptake. In this review, we introduce the methodologies used to assay glucose uptake and the usage of these methodologies in several areas of research.
Methods based on Radiolabeled Glucose Analogs
Glucose uptake in cultured cells and tissues is routinely determined by using non-metabolizable radioactive hexoses, such as 3MG or 2DG labeled with a high specific activity of [ 3 H] or [ 14 C]. Radiolabeled transporter substrates are particularly popular for glucose uptake studies as they provide a better signal-to-noise ratio and higher specificity than fluorescent labels. However, radioactive materials must be handled in a controlled and supervised area according to government regulations for the safe use of radioactive substances. All staff involved in the handling and use of radioactive material must receive training for this purpose as required by local bidirectional transfer of their substrates across membranes, and they may exhibit either symmetric or asymmetric transport kinetics, with passive diffusion down the concentration gradient of the substrate.
All mammalian cells contain one or more members of the GLUT family. The existence of multiple GLUT isoforms, with different kinetic properties and regulated cell surface expression, provides the basis for the fine tuning of glucose uptake, metabolism, and signal generation in order to preserve cellular and whole body metabolic integrity. GLUT1 and GLUT4 are well-characterized transporters that are expressed in various tissues (Charron et al., 1989; Gould and Holman, 1993) . In particular, GLUT1 is expressed in the plasma membrane and is responsible for the basal level of glucose uptake in metabolically active adipocytes and muscle cells, as well as in many other cell types. In contrast, GLUT4 is found in adipose tissues and skeletal/cardiac muscles and is known to be responsible for the regulation of cellular glucose uptake upon stimulation caused by external factors, such as insulin and exercise ( Figure 2) (Dawson et al., 2001; Mitsumoto and Klip, 1992) .
The various glucoregulatory functions are usually secondary to glucose uptake, a step that, in most tissues (with the notable exception of hepatocytes and pancreatic β-cells), is controlled by the level of GLUT expression at the cell sur- Park et al., 2007; Tian et al., 2009) (Gould and Holman, 1993; Rea and James, 1997; Simpson and Cushman, 1986) . Glucose enters the cell by a carrier-mediated, facilitated diffusion mechanism, which, in most tissues, has no energy or counter-ion requirements. In adipose tissues and skeletal muscle, glucose entry is acutely regulated by insulin and other hormones. Indeed, in those tissues, GLUT4 is the chief isoform which is, in basal conditions, retained in a specific intracellular storage compartment. The GLUT4-containing vesicles are translocated to the plasma membrane in response to insulin, thus allowing for the massive entry of glucose into the cells. Adipocytes also contain a small proportion of the ubiquitously expressed glucose transporter, GLUT1, which is at a similar concentration level at the plasma membranes and inside the cell. Because of this basal distribution, the insulin effect on GLUT1 translocation is minor. Fig. 3 . Schematic transport of glucose, 3-O-methyl-d-glucose (3MG) and 2-deoxy-d-glucose (2DG). Glucose transported through the glucose transporters (GLUTs) is further metabolized by subsequent steps in the pathways for glucose metabolism, and glucose and glucose-6-phosphate (G6P) do not accumulate in the cell. 3MG enters the cell through the GLUTs and is unable to undergo further metabolism. However, the cell membrane is permeable to 3MG. 2DG enters the cell through the GLUTs and is phosphorylated by hexokinase (HK). Due to low levels of intracellular phosphatase, 2-deoxyglucose-6-phosphate (DG6P) accumulates in the cell. DG6P is unable to undergo further metabolism.
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the widespread use of PET is hampered by high costs of cyclotrons needed to produce these short-lived radionuclides, and the need for specially adapted on-site chemical synthesis apparatus to produce the radiopharmaceuticals after radioisotope preparation. Because the half-life of fluorine-18 is about two hours, the prepared dose of a radiopharmaceutical bearing this radionuclide will undergo multiple half-lives of decay during the work day. For this reason, this technique is used primarily for clinical diagnosis or by well-funded laboratories.
Methods based on Unlabeled 2-Deoxyglucose (Enzymatic methods)
The 2DG-treated cells accumulate DG6P within the cytoplasm because 2DG is transported into cells, phosphorylated, then not metabolized further. To determine the concentration of accumulated DG6P in cells, non-radioisotopic enzymatic assays based on glucose 6-phosphate dehydrogenase (G6P-DH) have been developed. All of the methods are based on the following steps.
(1) DG6P is oxidized in the presence of a high concentration of G6PDH.
(2) NADPH produced in step 1 is then quantified either by the use of a recycling amplification enzymatic system or by measuring the fluorescence of NADPH. Endogenous or medium-derived glucose and glucose 6-phosphate (G6P) give rise to a high background as they are substrates for enzymes. To prevent this problem, researchers have contrived ways to eliminate these substrates or to separate the detection of glucose, G6P, 2DG, and DG6P. Endogenous NAD(H) and NADP(H) also affect the assays because G6PDH needs these nucleotide coenzymes, and the reduced form of the coenzymes gives rise to high back-ground. Fortunately, the elimination of these coenzymes is comparatively easy: e.g., NAD(P) + can be eliminated by heating under alkaline conditions, and NAD(P)H can be eliminated by heating under the acidic conditions.
Enzymatic fluorescence assay for 2DG uptake (Detection of NADPH fluorescence) NADP + and NADPH have different fluorescence signals. NADPH in solution has an emission peak at 460 nm when excited at 340 nm, while the oxidized form of the coenzyme does not fluoresce. Based on the detection of the fluorescence of NADPH, Manchester and coworkers and Sasson and coworkers developed methods for measuring DG6P in tissues and cultured cells (Manchester et al., 1990; Sasson et al., 1993) . The assay can be performed in multiwell plates and analyzed in a suitable plate-reader. Many cells are required for these assays, however, and cell extracts must be prepared because the fluorescence intensity of NADPH is and federal law.
Radiolabeled 3-O-Methylglucose 3MG is non-phosphorylatable glucose analog which can be used for the accurate measurement of the true initial glucose transport rate without interference with the subsequent glucose-metabolizing steps (e.g., phosphorylation to glucose-6-phosphate). The rate of 3MG transport is quantified using a modified version of the L-arabinose uptake method described Foley and coworkers. (Foley et al., 1978) . However, use of 3MG necessitates a very short incubation time because of the rapid equilibration of the analog across plasma membranes. The assay also requires either a rapid separation of cells from the incubation medium, usually by centrifugation through a suitable oil cushion, or the prevention of 3MG efflux by washing with a mercuric chloride solution. In the protocol detailed by Yamamoto et al, 3MG efflux is prevented by rinsing the cells quickly with ice-cold buffer instead of mercuric chloride solution (Yamamoto et al., 2012) .
Radiolabeled 2-Deoxyglucose Assaying the uptake of radiolabeled 2DG is more convenient than assaying the uptake of 3MG because 2DG is converted to a stable and impermeable derivative, 2-deoxyglucose 6-phosphate (DG6P). The method is based on the fact that glucose and 2DG are transported in the same manner into cells and phosphorylated by hexokinase (HK) or glucokinase. Unlike with glucose, the DG6P formed from 2DG accumulates because it cannot be converted to an analog of fructose 6-phosphate or otherwise rapidly metabolized (Figure 3 ). Sokoloff and coworkers described an autoradiographic method to measure the regional rate of brain glucose consumption using [ 14 C]-labeled 2DG (Sokoloff et al., 1977) . This method was subsequently employed extensively for studying glucose utilization in a variety of other tissues, including skeletal muscle and fat.
Positron emission tomography using [ 18 F]-FDG Positron emission tomography (PET) is a nuclear medicine imaging technique that produces a three-dimensional image of functional processes in the body (Pauwels et al., 2000) . This technique is very popular in diagnostics and has been integrated with computerised tomography (CT) technology (i.e. PET/CT) (Brush et al., 2011 ). The PET system detects pairs of gamma rays emitted indirectly by a positronemitting tracer, which is introduced into the body attached to a biologically active molecule. A radioactive modified HK substrate, [ 18 F]-labeled fluoro-2-deoxy-d-glucose (FDG), is a radiopharmaceutical commonly used in PET. FDG is taken up by cells with high glucose requirements, such as brain, kidney, and cancer cells, where phosphorylation prevents the glucose from being released from the cell once it has been absorbed. Minimization of the radiation dose to the subject is an attractive feature of short-lived radionuclides. However,
(2) Oxidation of G6P under at least 12 h-incubation with a low concentration of G6PDH plus NAD + to eliminate glucose and G6P. Phosphoglucose isomerase is added to facilitate the conversion of endogenous F6P to G6P. (3) Elimination of NAD(P)H with HCl, which removes endogenous NAD(P)H as well as NADH produced in step 2. (4) Production of NADPH through oxidation of DG6P with a high concentration of G6PDH, with the NADPH being used for quantification of DG6P. (5) Elimination of NAD(P) + and G6PDH remaining after step 3 with NaOH. (6) Recycling amplification reaction using GR and DTNB for the small amount of NADPH produced, and quantification of DG6P using a 96well microplate photometric reader. Enzymatic fluorescence assay for 2DG uptake (Amplification by the resazurin-diaphorase system) Electrons from NADPH (or NADH) are enzymatically transferred to nonfluorescent resazurin in the presence of diaphorase to produce resorufin, a highly fluorescent molecule. The use of the resazurin-diaphorase system enables the determination of dehydrogenase activities, which generate NADH or NADPH. Using the amplifying system, the author's group developed an enzymatic fluorescence assay for the determination of DG6P accumulated in cultured cells. This method provides a simpler technique for measuring 2DG uptake by a simple incubation with a single total-assay reaction mixture, coupled with fluorescence detection (Yamamoto et al., 2006) . Next, our group proposed the same assay for use with animal tissues. To determine 2DG, DG6P, glucose and G6P, this simple procedure involves the incubation of samples with four independent single reaction mixtures followed by measurement of fluorescence. From differences between the values obtained with the four reactions, glucose, G6P, 2DG and DG6P could be quantified in a sensitive manner ( Figure 4 ) (Yamamoto et al., 2010; Yamamoto et al., 2008) . Recently, a step-by-step protocol for the measurement of 2DG uptake in cultured cells was published (Yamamoto et al., 2012) . This method is based on the direct fluorometric measurement of resorufin generated in the presence of NADPH. This chain reaction continues until DG6P is consumed. This endpoint assay can be conducted in a 96-well or 384-well format.
Method based on Fluorescent Glucose Analogs
2 or 6-NBDG (fluorescent derivatives of d-glucose) Yoshioka and coworkers synthesized and studied a fluorescent analogue of 2-deoxyglucose, 2-(N-(7-nitrobenz-2-oxa-1,3-rather low. Moreover, if the test compound has UV absorbency and adheres to the cell membrane, the measurement of 2DG uptake into cells may be affected since the wavelength used to detect NADPH fluorescence is in the UV range.
Enzymatic photometric assay for 2DG uptake Amplification by enzymatic cycling provides a methodology for virtually unlimited amplification of analytical sensitivity. The most widely applicable cycling systems are those for NAD + and NADP + because these can be used to increase the sensitivity of methods for a host of other substances. The microanalytical methodology developed by Oliver Lowry provides a basis for measuring directly, and with high precision, enzyme activities and metabolites from single cells. A number of cycling procedures were developed by him and his students (Lowry, 1980) . As an aside, Lowry is very famous as the inventor of the Lowry method for the quantification of protein. Several methods use these cycling amplification systems, and all are based on G6PDH coupled with the conversion of NADP + to NADPH.
To measure 2DG uptake in tissues, glucose and G6P must either be eliminated or 2DG, G6P, and DG6P must be individually detected because the tissue levels of glucose are much higher than those of 2DG and DG6P. To quantify 2DG and DG6P, Chi and coworkers and Akabayashi and coworkers developed enzymatic assays (Akabayashi et al., 1989; Chi et al., 1978; Chi et al., 1993; Chi et al., 1987) . Their methods are based on the HK-G6PDH assay described above and either directly detect NADPH derived from the reactions or detect NADPH by amplification with NADP cycling reagents. They also used elimination reaction steps in their methods. To eliminate glucose, Chi and coworkers used glucose oxidase and mutarotase, which convert glucose to glucono-δ-lactone. To eliminate glucose and G6P, Akabayashi and coworkers adopted the reactions containing HK, glucose phosphate isomerase and phosphofructokinase by converting these substrates to fructose 1,6-diphosphate. However, although they have refined their methods several times, their protocols remain complicated.
Recently, Minokoshi's laboratory evaluated and optimized a non-radioisotopic enzymatic assay based on previously described methods (Saito et al., 2011) . To determine NADPH produced from the reaction of G6PDH, they used recycling amplification using glutathione reductase (GR) and 5,50-dithiobis(2-nitrobenzoic acid) (DTNB) (Jorgensen and Rasmussen, 1979) . They optimized the enzyme reaction for complete oxidation of endogenous G6P and glucose in mouse tissues in vivo and in serum, as well as in 3T3-L1 adipocytes in vitro. The Saito method has six key steps:
(1) Conversion of glucose to G6P, and 2DG to DG6P, by HK, ATP, and MgCl 2 .
series of experiments has been conducted to define the optimal conditions for this assay, they have to date failed to demonstrate the clear-cut stimulation of 2NBDG transport into these cells by insulin (Zou et al., 2005) . The limitation in the use of 2NBDG is related to its intracellular fate. 2NBDG is metabolized to a phosphorylated fluorescent derivative at the C-6 position (2NBDG 6-phosphate) after entering cells and then decomposes to a non-fluorescent derivative. This analogue has been widely used in various studies, especially for tumor imaging and examination of GLUT-related cell metabolism (Ball et al., 2002) . Yamada and coworkers demonstrated a step-by-step protocol for monitoring glucose uptake into single, living cells using 2NBDG (Yamada et al., 2007) . Also, the nonmetabolizable fluorescent glucose analog, 6-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-6deoxy-d-glucose (6NBDG), has been increasingly used to study glucose transport and metabolism in many cell types besides astrocytes and neurons (Chuquet et al., 2010) . Fluorescent glucose analogues linked to a fluorophore diazol-4-yl)-amino)-2-deoxy-d-glucose (2NBDG) (Yoshioka et al., 1996) . Since 2NBDG has poor photophysical properties in aqueous solution and does not compete strongly with d-glucose during cellular uptake under physiological conditions, this analog was not suitable for monitoring glucose uptake in mammalian cells. However the recent development of advanced photomultipliers which provide extremely high sensitivity and ultra-fast response have made the use of 2NBDG practical. Direct visualization of glucose uptake without using isotopes makes the 2NBDG method quite attractive. However, care should be taken because fluorescence intensity is an arbitrary measurement, so quantification requires a stable system as well as accurate procedures. Zou and coworkers described a sensitive assay for the direct and rapid measurement of glucose transport in single mammalian cells. The assay is based on the direct incubation of cells with 2NBDG, followed by flow cytometric detection of the total fluorescence produced by the cells due to the accumulation of 2NBDG-6-phosphate with time. However, although a . Assay cocktail A detects total glucose, 2DG, G6P and DG6P. Assay cocktail B detects total glucose and G6P. Assay cocktail C detects total G6P and DG6P and assay cocktail D detects only G6P. For in vitro studies, the use of assay cocktail C alone permits evaluation of 2DG uptake in cultured cells (Yamamoto et al., 2012) . Abbreviations: 2DG, 2-deoxyglucose; G6P, glucose-6-phosphate; DG6P, 2-deoxyglucose-6-phosphate; 6PGA, 6-phosphoglucuronic acid; 6PDGA, 6-phospho-2-deoxyglucuronic acid; HK, hexokinase; G6PDH, glucose-6-phosphate dehydrogenase.
and Sabatini, 2008; Warburg, 1956a; b; Weber, 1977) . Avidity to glucose in tumors is now believed to be fundamental to supporting bioenergetics and biosynthetic demands for uncontrolled proliferation consequent to tumor transformation. Recent studies have uncovered the molecular basis for metabolic alterations responsible for elevated glucose uptake and utilization, providing a more detailed understanding of the biological relationships underlying cancer development. Many human cancers have been found to express elevated levels of the GLUT1 glucose transporter compared to normal tissues (Yamamoto et al., 1990; Younes et al., 1995) . The Warburg effect has important medical applications, as high aerobic glycolysis by malignant tumors is utilized clinically to diagnose and monitor treatment responses of cancers by imaging uptake of [ 18 F]-FDG with PET (Pauwels et al., 2000) . For in vitro study, the Warburg effect can be assessed by using an uptake assay of fluorescence 2DG analog (O'Neil et al., 2005) or an enzymatic fluorescence glucose uptake assay (Zhu et al., 2009) . Glucose uptake assays in immunological studies (Mitogen-Induced Lymphocyte Activation) T lymphocytes play a critical role in cell-mediated immune responses. Cultured lymphocytes can be stimulated to a proliferative response and to DNA synthesis by various mitogens. During activation, extracellular and intracellular signals alter T cell metabolism in order to meet the energetic and biosynthetic needs of a proliferating, active cell. T cell stimulation strongly induces glucose uptake and glycolysis. T cells are dependent on external supplies of glucose to maintain biosynthesis and energy metabolism during activation. Activated T cells adopt a metabolic state of ''aerobic glycolysis'', in which glucose flux through glycolysis is high, but only a small proportion of the glucose is oxidized in mitochondria (Cooper et al., 1963; Culvenor and Weidemann, 1976; Hedeskov, 1968; Roos and Loos, 1970; Sagone et al., 1974) . T cell activation is accompanied by a large increase in glucose uptake and glycolysis, which is necessary to support new metabolic demands. Numerous studies have shown that enhanced glucose utilization is dependent on signals from the co-stimulatory receptor CD28, and particularly the PI3K/Akt pathway (Frauwirth et al., 2002; Parry et al., 2005) . Recently, Marko and coworkers showed that the MAPK family member ERK plays an important role in the regulation of glucose metabolism during T cell activation, while p38 makes a smaller (and perhaps redundant) contribution (Marko et al., 2010) . During lymphocyte proliferation caused by mitogen stimulation as well as by permanent transformation into lymphoblastoid cell lines, glucose metabolism is altered not only quantitatively but also qualitatively by changing from partly aerobic to almost completely anaerobic glucose breakdown. The changes in meta-To overcome the limitations of 2NBDG, such as weak fluorescence intensity, high treatment dosage, and incompatibility with physiological conditions, Park and coworkers previously reported a fluorescent glucose bioprobe. This bioprobe is a fluorescent glucose analogue constructed by joining a Cy3 fluorophore to the α-anomeric position of d-glucose with a linker (GB1-Cy3). They demonstrated its application in fluorescence-based monitoring of cellular glucose uptake in cancer cells. The use of GB1-Cy3 clearly differentiated the increased cellular uptake of glucose in cancer cells and its drastic reduction upon treatment with anticancer agents. (Park et al., 2007) . In addition, they developed a two-photon glucose tracer, AG2, that can be excited by a 780 nm fs laser pulse and used to monitor glucose uptake in normal and colon-cancer tissues from human patients for more than 3000 s, thus allowing visualization of the therapeutic efficacy of anticancer agents (Tian et al., 2009 ). Furthermore, Lee and coworkers recently developed a fluorescent glucose bioprobe, GB2-Cy3, for the real-time and quantitative monitoring of glucose uptake in living cells. Flow cytometry and fluorescence microscopy analyses revealed that GB2-Cy3 is ten times more sensitive than 2NBDG, a leading fluorescent glucose bioprobe. GB2-Cy3 can also be utilized for the quantitative flow cytometry monitoring of glucose uptake in metabolically active C2C12 myocytes under various treatment conditions .
Applications of Glucose Uptake Assays
Methods for the evaluation of glucose uptake are applied in a wide range of fields because facilitative glucose transport systems are ubiquitous in animal cells and are responsible for transporting glucose across the cell membrane.
Glucose uptake assays in anticancer research (Warburg Effect) Otto Warburg pioneered quantitative investigations of cancer cell metabolism, as well as photosynthesis and respiration. Warburg and coworkers showed in the 1920s that, under aerobic conditions, tumor tissues metabolize approximately tenfold more glucose to lactate in a given time than normal tissues, a phenomenon known as the Warburg effect (Koppenol et al., 2011) . Metabolism, and especially glucose uptake, is a key quantitative cell trait that is closely linked to cancer initiation and progression. Tumor cells are dependent on glycolysis to support their metabolic requirements. Even under aerobic conditions, tumor cells continue to rely on glycolysis rather than oxidative phosphorylation, resulting in high glucose requirements to generate energy and support metabolic function. This process is defined molecularly by a dramatic increase in extracellular glucose consumption, accompanied by an elevated rate of lactate excretion, regardless of oxygen abundance (Deberardinis et al., 2008; Hsu of raised glucose in neurons and how this can explain the major components of diabetic neuropathy (Tomlinson and Gardiner, 2008) This research area originally stimulated the development of advanced glucose uptake assays (Sokoloff et al., 1977) .
Glucose uptake assay in anti-obesity and anti-diabetes studies The pathogenesis of diabetes and metabolic syndrome is complicated. The global incidence of T2DM is increasing rapidly, with high rates of morbidity and mortality, resulting in significant financial and social burden worldwide (Zimmet et al., 2001) . T2DM is characterized by insulin resistance and hyperglycemia, which lead to chronic complications in both small and large blood vessels. In brief, insulin resistance is a condition in which the body cells become resistant to insulin. When glucose levels stay elevated, the pancreas will keep secreting insulin and the glucose will be utilized by the cells. The excess glucose will be transformed into glycogen and fat and stored in muscle cells and adipose cells, respectively. Finally, the muscle and fat cells stop responding to insulin. This leads to the condition called insulin resistance, and a normal level of insulin is not able to activate the cells to take up the glucose. This chronically elevated glucose level will lead obesity and finally lead to the condition called T2DM.
Two major transporters, GLUT4 and GLUT1, are expressed in adipose tissue and skeletal muscle. GLUT1 is thought to play a constitutive role, and is responsible for basal glucose uptake. GLUT4 is known to be responsible for the regulation of cellular glucose uptake upon stimulation by external factors, such as insulin and exercise. The skeletal muscle's uptake of glucose is an important area for study, because glucose transport in skeletal muscle is the major rate-limiting step in glucose utilization. Since skeletal muscle is the largest organ system in the body responsible for using glucose, it is important to understand how glucose is transported across the plasma membrane and utilized for energy production in muscle tissue. The level of cellular glucose uptake can be controlled by the translocation of GLUT4 from its intracellular storage sites to the plasma membrane. This translocation is controlled by two different signaling pathways: the insulin-dependent signaling pathway and the insulin-independent AMPK signaling pathway (Figure 2) . The former pathway is triggered by the binding of secreted insulin to insulin receptors. Subsequent activation of downstream signaling proteins, such as PI3K and Akt (Cho et al., 2001; Saltiel and Kahn, 2001) , Cbl (Ribon and Saltiel, 1997) , and mitogen-activated protein kinase (MAPK) (Fujishiro et al., 2001) , leads to GLUT4 translocation to the plasma membrane (Slot et al., 1991) . In contrast, muscle contraction and exercise cause an increase in the cellular AMP/ bolic rates observed in proliferating as well as in transformed or leukemic lymphocytes appear to be reliable parameters to characterize the state of lymphocyte activation or to evaluate the efficacy of lymphokines (Brand et al., 1986) . Thus, glucose uptake assays are used to evaluate T cell activation in conjunction with cell proliferation, glycolysis, and HK assays.
Glucose uptake assays in neurological studies It is well known that the brain and the nervous system can only use glucose or ketone bodies as energy sources. Unlike most cells, brain cells are constantly in a state of metabolic activity. Even when a person is sleeping, brain cells are busy fixing things upstairs to keep the body running smoothly. The concept of a metabolic coupling between neurons and glia, particularly astrocytes, geared at maintaining energy metabolism homeostasis in the brain, has been entertained for some time. The contribution of astrocytes to glucose utilization during neuronal activity is even more striking. Indeed, astrocytes are ideally positioned to provide coupling between neuronal activity and glucose uptake. As noted in the introductory remarks, astrocyte end-feet surround intraparenchymal capillaries, which are the source of glucose. This cytoarchitectural arrangement implies that astrocytes form the first cellular barrier that glucose entering the brain parenchyma encounters, making astrocytes a likely site of primary glucose uptake (Tsacopoulos and Magistretti, 1996) . Numerous studies, predominantly in rodent brain, lead to the conclusion that glucose delivery and utilization in the mammalian brain is primarily mediated by both GLUT1 and GLUT3: a high molecular weight form of GLUT1 in the endothelial cells of the microvessels that comprise the blood brain barrier, GLUT3 in all neuronal populations, and a lower molecular weight, less glycosylated form of GLUT1 in the remainder of the brain parenchyma (Simpson et al., 2008) . In their review article, Simpson and coworkers discussed the properties and tissue and cellular localization of GLUT3, as well as the features of expression, function, and regulation that distinguish it from the rest of its family and make it uniquely suited as the mediator of glucose delivery to these specific cells (Simpson et al., 2008) . Neurons have been classically considered insulin-insensitive cells. Whatever the mechanism of glucose distribution between astrocytes and neurons, the question arises whether brain cells take up glucose in proportion to their energetic needs. Neurons have a constantly high glucose demand, and unlike muscle cells they cannot accommodate episodic glucose uptake under the influence of insulin. Neuronal glucose uptake depends on the extracellular concentration of glucose, and cellular damage can ensue after persistent episodes of hyperglycaemia -a phenomenon referred to as glucose neurotoxicity. Tomlinson and Gardiner reviewed the pathophysiological manifestation foods. In the present review, we introduced the methodologies used to assay glucose uptake and their applications. This information might be useful not only in the developments of drugs, but also in studies of food factor function, and the molecular targets of food factors in chemoprevention, diabetes, dementia, and anti-aging. ATP ratio; subsequent phosphorylation at Thr-172 of AMP kinase (AMPK) can trigger the insulin-independent signaling pathway. AMPK plays a crucial role as an energy sensor in metabolic tissues and stimulates glucose uptake in skeletal muscles (Rutter et al., 2003; Winder, 2001) .
Development of safe and effective drugs or health foods against diabetes and metabolic syndrome remains challenging. Therefore, glucose uptake assays are used on a routine basis in this field, and researchers are engaged in discovering and evaluating promising anti-diabetic compounds by targeting the key molecules or pathways involved in these diseases.
Conclusion
Evaluation of glucose uptake is crucial in the study of numerous diseases because facilitative glucose transport systems are ubiquitous in animal cells and are responsible for transporting glucose across the cell membrane. In particular, glucose uptake assays are very often used in studies of obesity and diabetes because coordination of energy use and food intake is necessary for the regulation of body weight.
Over the past several decades, glucose uptake assays using radiolabeled hexoses have proven to be indispensable tools in biomedical research and have played a pivotal role in the investigation of absorption, distribution, and metabolism properties of glucose utilization. The development of enzymatic methodologies has eliminated the need for radioisotopes and allows high-throughput. Natural products provide a rich resource for the development of novel therapeutic agents used to treat a variety of human diseases. Developments in food research have resulted in increased knowledge about the molecular mechanism of the physiological action of foods. This allows us to design a basic strategy for the practical use of food functions, not only in disease prevention but also in conjunction with modern medical treatment to improve therapeutic efficacy or to reduce side effects. Foods can be regarded as functional if proven to affect beneficially one or more target functions in the body, beyond adequate nutritional effects, in a way relevant to an improved state of health and well-being, reduction of risk of diseases, or both. Functional foods might have a particularly high impact on the prevention or treatment of obesity and diabetes for which, more than in many other fields, the link between nutrition, biological responses and diseases is clearly established. We must learn more about the similarity and difference in the mode of action of foods or food factors and drugs. Additionally, we need to consider several topics such as oxidative stress as a modulator of food factor function, and the molecular targets of food factors in chemoprevention, diabetes, dementia, and anti-aging. Further discussions will be focused on strategies for applying food function in supplements and functional
